The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 29, 2024

Filed:

Aug. 21, 2020
Applicants:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Yale University, New Haven, CT (US);

Institute for Research IN Biomedicine (Irb), Bellinzona, CH;

Inventors:

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Sean Stevens, San Diego, CA (US);

Chozhavendan Rathinam, Yonkers, NY (US);

Elizabeth Eynon, New Haven, CT (US);

Markus Manz, Zollikon, CH;

Richard Flavell, Guilford, CT (US);

George D. Yancopoulos, Yorktown Heights, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01K 67/0278 (2024.01); A01K 67/027 (2024.01); A01K 67/0271 (2024.01); A61K 49/00 (2006.01); C12N 15/85 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); A01K 67/027 (2013.01); A01K 67/0271 (2013.01); A61K 49/0008 (2013.01); C12N 15/8509 (2013.01); G01N 33/5088 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/072 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); A01K 2267/0337 (2013.01); C12N 2015/8536 (2013.01); G01N 2500/10 (2013.01);
Abstract

Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.


Find Patent Forward Citations

Loading…